Goldman Sachs Group Inc. Acquires 467,270 Shares of Bausch Health Cos Inc. $BHC

Key Points

• Goldman Sachs Group Inc. increased its holdings in Bausch Health Cos by 97.1% during the first quarter, now owning approximately 0.26% of the company worth $6,136,000.
• Bausch Health Cos shares are currently valued at $7.17 and reported a negative return on equity of 852.36% for the most recent quarter.
• Insider activity shows Director John Paulson acquired over 34 million shares, raising his stake significantly, alongside other institutions boosting their positions in Bausch Health.

Goldman Sachs Group Inc. increased its position in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 97.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 948,322 shares of the company's stock after purchasing an additional 467,270 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.26% of Bausch Health Cos worth $6,136,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cary Street Partners Financial LLC bought a new position in Bausch Health Cos in the first quarter worth $27,000. Caitong International Asset Management Co. Ltd bought a new position in Bausch Health Cos in the first quarter worth $27,000. SBI Securities Co. Ltd. lifted its position in Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares during the period. Wealthquest Corp bought a new position in Bausch Health Cos in the first quarter worth $58,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Bausch Health Cos in the first quarter worth $68,000. 78.65% of the stock is owned by institutional investors.

Insider Buying and Selling at Bausch Health Cos

In other news, Director John Paulson bought 34,721,118 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the purchase, the director owned 70,755,869 shares of the company's stock, valued at $636,802,821. This represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have acquired 37,964,167 shares of company stock valued at $333,757,793 over the last three months. 19.97% of the stock is currently owned by company insiders.

Bausch Health Cos Stock Down 2.3%

Shares of BHC traded down $0.16 during mid-day trading on Friday, hitting $6.73. 1,404,712 shares of the company's stock were exchanged, compared to its average volume of 2,073,771. The company has a market cap of $2.49 billion, a PE ratio of 25.89 and a beta of 0.48. Bausch Health Cos Inc. has a 52 week low of $4.25 and a 52 week high of $9.85. The company has a 50-day simple moving average of $6.90 and a 200 day simple moving average of $6.09. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.07). The business had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Bausch Health Cos has set its FY 2025 guidance at EPS. On average, research analysts forecast that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Three analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.00.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.